IMAC

IMAC Holdings, Inc. [IMAC] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

IMAC Stock Summary

In the News

11:04 29 Mar 2024 IMAC

Best Penny Stocks To Buy? Einhorn, Lynch, Cohen & Dalio Own These 5

Top Wall Street Investors Own These 5 Penny Stocks. Are They A Buy Now?

09:59 29 Mar 2024 IMAC

Legendary Investor Peter Lynch Just Bet on IMAC Stock. 9 Things to Know.

IMAC stock is soaring higher today on news that legendary investor Peter Lynch has taken a stake in little-known IMAC Holdings. The post Legendary Investor Peter Lynch Just Bet on IMAC Stock.

02:32 29 Mar 2024 IMAC

Time to Take Profits on IMAC Stock After Shares Soar on Walmart News

It is time to sell your IMAC stock and make a nice profit on the recent rally because the company hasn't shown the ability to make profits. The post Time to Take Profits on IMAC Stock After Shares Soar on Walmart News appeared first on InvestorPlace.

04:07 29 Mar 2024 IMAC

Best Reddit Penny Stocks To Buy Now? 5 Trending Stocks To Watch Today

What are the best penny stocks to buy today? The post Best Reddit Penny Stocks To Buy Now?

04:04 29 Mar 2024 IMAC

Will IMAC Holdings, Inc. (IMAC) Report Negative Q2 Earnings? What You Should Know

IMAC Holdings, Inc. (IMAC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

06:01 29 Mar 2024 IMAC

IMAC Holdings to Present at the Summer Solstice - Best Ideas from the Buy Side Conference on Tuesday, June 1, 2021

Brentwood, Tenn, May 26, 2021 (GLOBE NEWSWIRE) -- IMAC Holdin gs, Inc. (Nasdaq: IMAC, IMACW), a provider of innovative medical advancements and care specializing in regenerative and rehabilitation orthopedic treatments without the use of surgery or opioids, announced today that management has been invited to present at the Summer Solstice - Best Ideas from the Buy Side Conference, which is being held virtually on June 1 – June 4, 2021.

05:50 29 Mar 2024 IMAC

IMAC Holdings Announces Pricing of its Public Offering of Common Stock

Brentwood, Tenn, March 23, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (the “Company” or “IMAC”) (Nasdaq: IMAC, IMACW), a provider of innovative medical advancements and care specializing in regenerative and rehabilitation orthopedic treatments without the use of surgery or opioids, announced today the pricing of its underwritten registered public offering of 10,625,000 shares of its common stock at a public offering price of $1.60 per share, for total gross proceeds of $17.0 million. The net proceeds, after underwriting discounts, but before estimated expenses of the offering payable by IMAC, are expected to be approximately $16.0 million. All shares of common stock to be sold in the offering will be sold by the Company, except that the Company, together with its co-founder and chief operating officer as a selling stockholder, will grant the underwriter for the offering a 45-day option to purchase up to 15% of the shares of common stock in the offering. The offering is expected to close on or about March 26, 2021, subject to the satisfaction of customary closing conditions.

09:00 29 Mar 2024 IMAC

IMAC Holdings Reports 2020 Financial Results and Corporate Update

BRENTWOOD, Tenn., March 04, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or the “Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announced financial results for the year ended December 31, 2020.

09:25 29 Mar 2024 IMAC

IMAC Holdings, Inc. Announces Completion of First Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson's Disease

BRENTWOOD, Tenn, March 01, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or “the Company”), today announces it has completed the first cohort of its Phase 1 clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson's disease.

09:00 29 Mar 2024 IMAC

IMAC Holdings Adds Regenerative Wound Care Service in Regeneration Centers

Insurance to Reimburse Services Providing Cell-Based Amniotic-Infused Mesh Application to Chronic Non-Healing Wounds and Diabetic Foot Ulcers

IMAC Financial details

Company Rating
Buy
Market Cap
33.08M
Income
-24.42M
Revenue
8.47M
Book val./share
0.93
Cash/share
0.2
Dividend
-
Dividend %
-
Employees
154
Optionable
No
Shortable
Yes
Earnings
15 Aug 2022
P/E
32.51
Forward P/E
-
PEG
6.35
P/S
-
P/B
4.35
P/C
5.05
P/FCF
0.01
Quick Ratio
1.02
Current Ratio
1.18
Debt / Equity
1.09
LT Debt / Equity
0.76
-
-
EPS (TTM)
-22.33
EPS next Y
-
EPS next Q
-
EPS this Y
92.15%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
17.54%
Revenue last 5Y
19.29%
Revenue Q/Q
16.51%
EPS Q/Q
107.09%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0.02%
Inst Trans
0.9%
ROA
9%
ROE
27%
ROC
-0.32%
Gross Margin
25%
Oper. Margin
-111%
Profit Margin
37%
Payout
-
Shs Outstand
32.75M
Shs Float
26.52M
-
-
-
-
Target Price
-
52W Range
-
52W High
-
52W Low
-
RSI
41
Rel Volume
-
Avg Volume
-
Volume
81.45K
Perf Week
250.57%
Perf Month
380.27%
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
-0.885873
-
-
Volatility
0.25%, 0.13%
Prev Close
288.31%
Price
1.01
Change
278.99%

IMAC Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
27.7658.5334.8519.1417.17
Net income per share
-12.65-28.55-15.11-14.77-28.38
Operating cash flow per share
-7.49-15.74-16.27-10.1-10.92
Free cash flow per share
-14.03-20.39-17.28-11.11-11.27
Cash per share
0.81.457.129.470.81
Book value per share
-9.5538.7628.3223.884.94
Tangible book value per share
-42.38-4.92-2.289.973.49
Share holders equity per share
-9.5538.7628.3223.884.94
Interest debt per share
24.835.926.348.534.42
Market cap
26.65M11.63M16.91M25.71M5.64M
Enterprise value
32.29M19.64M23.42M24.49M9.03M
P/E ratio
-8.73-1.58-3.04-2.32-0.21
Price to sales ratio
3.980.771.321.790.35
POCF ratio
-14.74-2.86-2.82-3.39-0.55
PFCF ratio
-7.87-2.21-2.66-3.08-0.53
P/B Ratio
-11.561.161.621.431.21
PTB ratio
-11.561.161.621.431.21
EV to sales
4.821.31.821.70.56
Enterprise value over EBITDA
-10.84-4.23-4.94-2.97-1.1
EV to operating cash flow
-17.86-4.83-3.91-3.23-0.88
EV to free cash flow
-9.53-3.73-3.68-2.93-0.85
Earnings yield
-0.11-0.63-0.33-0.43-4.74
Free cash flow yield
-0.13-0.45-0.38-0.32-1.88
Debt to equity
-2.530.840.880.330.89
Debt to assets
0.530.410.460.220.38
Net debt to EBITDA
-1.89-1.73-1.370.15-0.41
Current ratio
0.050.420.81.841.13
Interest coverage
-23.09-6.89-11.5-19.74-694
Income quality
0.480.591.080.720.56
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.171.061.21.371.35
Research and developement to revenue
00000
Intangibles to total assets
0.570.450.440.380.12
Capex to operating cash flow
0.870.290.060.10.03
Capex to revenue
-0.24-0.08-0.03-0.05-0.02
Capex to depreciation
-2.43-0.77-0.21-0.46-0.2
Stock based compensation to revenue
00.030.030.040.03
Graham number
52.14157.7998.1489.0956.13
ROIC
-0.83-0.28-0.27-0.36-1.12
Return on tangible assets
-0.64-0.66-0.5-0.66-2.75
Graham Net
-60.41-42.59-21.77-1.54-3.62
Working capital
-13.16M-3.49M-1.19M4.13M494.1K
Tangible asset value
-10.23M-1.27M-839.09K7.49M3.29M
Net current asset value
-14.34M-9.9M-7.18M-208.63K-2.22M
Invested capital
-2.530.840.880.330.89
Average receivables
395.63K780.98K1.39M1.36M2.05M
Average payables
659.12K2.09M2.3M2.11M2.11M
Average inventory
0156.13K310.82K250.52K193.89K
Days sales outstanding
16.5430.3643.0530.6864.97
Days payables outstanding
493.07418.07380.35565.66412.02
Days of inventory on hand
044.8769.5342.9647.46
Receivables turnover
22.0712.028.4811.95.62
Payables turnover
0.740.870.960.650.89
Inventory turnover
08.145.258.57.69
ROE
1.32-0.74-0.53-0.62-5.75
Capex per share
-6.54-4.64-1-1.02-0.35

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
4.143.21.91.221.41
Net income per share
-6.91-10.59-7.84-1.27-2.63
Operating cash flow per share
-2.58-1.91-1.29-0.23-1.16
Free cash flow per share
-2.61-1.96-1.29-0.23-1.16
Cash per share
3.10.70.350.220.2
Book value per share
12.644.290.91-0.320.93
Tangible book value per share
6.153.03-0.18-1.140.14
Share holders equity per share
12.644.290.91-0.320.93
Interest debt per share
5.093.842.161.910.95
Market cap
10.39M6.48M4.72M3.65M2.22M
Enterprise value
12.21M9.88M6.7M5.48M3.12M
P/E ratio
-0.41-0.14-0.14-0.65-0.19
Price to sales ratio
2.751.872.262.711.42
POCF ratio
-4.41-3.13-3.33-14.43-1.73
PFCF ratio
-4.35-3.06-3.33-14.43-1.73
P/B Ratio
0.91.394.74-10.162.16
PTB ratio
0.91.394.74-10.162.16
EV to sales
3.222.853.24.081.99
Enterprise value over EBITDA
-6.11-4.47-3.25-5.44-1.09
EV to operating cash flow
-5.18-4.76-4.73-21.7-2.43
EV to free cash flow
-5.11-4.66-4.73-21.7-2.43
Earnings yield
-0.61-1.77-1.83-0.38-1.31
Free cash flow yield
-0.23-0.33-0.3-0.07-0.58
Debt to equity
0.40.892.38-5.811.09
Debt to assets
0.250.380.410.450.26
Net debt to EBITDA
-0.91-1.53-0.96-1.82-0.31
Current ratio
1.681.130.510.330.84
Interest coverage
-838.81-1.06K-914.14-61.7740.34
Income quality
0.370.30.380.180.45
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.391.471.821.590.72
Research and developement to revenue
00000
Intangibles to total assets
0.320.120.210.190.2
Capex to operating cash flow
0.010.02000
Capex to revenue
-0.01-0.01000
Capex to depreciation
-0.06-0.17000
Stock based compensation to revenue
0.020.030.040.03-0.03
Graham number
44.3531.9912.653.057.41
ROIC
-0.12-0.32-0.93-0.38-0.91
Return on tangible assets
-0.5-1.18-1.86-0.37-0.86
Graham Net
-1.88-3.15-3.25-3.8-2.18
Working capital
2.63M494.1K-1.73M-2.65M-387.69K
Tangible asset value
5.62M3.29M-203.31K-1.26M159.37K
Net current asset value
-493.36K-2.22M-3.04M-3.73M-1.16M
Invested capital
0.40.892.38-5.811.09
Average receivables
3.11M3.02M1.98M877.95K707.44K
Average payables
789.37K1.64M1.82M2.19M2.07M
Average inventory
147.6K158.67K167.02K120.04K98.9K
Days sales outstanding
75.0174.746.3245.4442.32
Days payables outstanding
507.81413.17654.751.25K167.37
Days of inventory on hand
38.9947.5946.6352.319.44
Receivables turnover
1.21.21.941.982.13
Payables turnover
0.180.220.140.070.54
Inventory turnover
2.311.891.931.729.54
ROE
-0.55-2.47-8.663.91-2.83
Capex per share
-0.03-0.04000

IMAC Frequently Asked Questions

What is IMAC Holdings, Inc. stock symbol ?

IMAC Holdings, Inc. is a US stock , located in Brentwood of Tennessee and trading under the symbol IMAC

What is IMAC Holdings, Inc. stock quote today ?

IMAC Holdings, Inc. stock price is $1.01 today.

Is IMAC Holdings, Inc. stock public?

Yes, IMAC Holdings, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Similar Market Cap